🌟 Join us in Unleashing the Power of Life Sciences to Save Lives! 🌟 At San Diego Regenerative Medicine Institute (https://www.sdrmi.org), we develop scalable health solutions for life-threatening and devastating diseases, such as heart disease and failure, stroke, Parkinson&rsquo;s disease (PD), Alzheimer disease (AD), spinal cord injury (SCI), traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), through most advanced, cutting-edge stem cell research. Every act of kindness, every dollar, and every moment of your time brings us closer to achieving our mission. Together, we can deliver urgently-needed, life-saving stem cell therapies to patients.&nbsp; How you can help power our mission:<ol fr-original-style="" style="width: 100%; box-sizing: inherit;"><li fr-original-style="" style="box-sizing: inherit;">Donate: Every dollar counts. Your contribution helps save lives. Give now to help us reach our goal.</li><li fr-original-style="" style="box-sizing: inherit;">Share: Share our campaign with your friends, family, and on social media. Your advocacy can amplify our impact.</li><li fr-original-style="" style="box-sizing: inherit;">Volunteer: Your time and skills can make an impact too.</li></ol>Thank you for supporting our mission, your support is invaluable. San Diego Regenerative Medicine Institute (SDRMI) was founded to leverage human embryonic stem cell (hESC)-based regenerative medicine development and manufacturing innovations to provide the next generation of cell-based therapeutic solutions for the unmet medical needs of many major health problems. SDRMI is a major innovator in the stem cell research and regenerative medicine market, and uniquely holds the key breakthrough technologies and exclusive rights for the major bottlenecks in the regenerative medicine market, including large-scale production of high quality, clinical-grade pluripotent hESC lines and their functional human heart and neuronal cell therapy products for commercial and therapeutic uses. SDRMI&rsquo;s hESC-based PluriXcel technology platforms provide clinical-grade translating and scale-up manufacturing capabilities to address key challenges to traditional medicine and bio-fabrication. Medical innovations of PluriXcel Platforms provide scalable platforms to ensure a high degree of efficacy and safety of hESC-derived regenerative medicine advanced therapy (RMAT) products, thus robust clinical benefits leading to therapies. Manufacturing innovations of PluriXcel Platforms provide scalable cGMP manufacturing capability for production scale-up of large quantities of high quality, clinical-grade hESC-based cell therapy products to support clinical trials and tissue/organ bio-fabrication, improving the availability, reproducibility, accessibility, and standardization of manufacturing materials, technologies, and processes to create human replacement cells, tissues, and organs. SDRMI&rsquo;s breakthrough hESC technology platforms not only constitute clinically representative progresses in both human cardiac and neuronal stem cell therapy products for treating a wide range of incurable or hitherto untreatable heart and neurological diseases and injuries, but also offers manufacturing innovation for production scale-up.&nbsp;&nbsp; Lack of a scalable human cardiac stem cell source with adequate heart muscle regeneration potential remains a major setback for heart replacement, and fabricating a human heart is still beyond reach. SDRMI&rsquo;s innovative PluriXcel-SMI-Heart Platform enables direct conversion of non-functional, clinical-grade hESCs at the pluripotent stage by small molecule induction uniformly into a large supply of human cardiac precursor cells and contractile cardiomyocytes (the mature contracting heart muscle cells), providing the scalable manufacturing capability for large-scale production of high-quality, clinical-grade human heart muscle cells adequate for heart muscle regeneration and bio-fabrication to fill the capability gap in myocardial tissue and contractile function restoration for heart disease and failure. SDRMI&rsquo;s hESC-based medical breakthrough innovation offers the only scalable source of human cardiomyocytes adequate for heart muscle regeneration and contractile function restoration to treat heart disease and failure, and for heart bio-fabrication to meet the demand of replacement hearts in organ transplantation. SDRMI has secured the patent [USPTO# 9,428,731] and exclusive rights for the development and commercialization of relevant hESC-based heart cell therapy products and tools.&nbsp; <img src="https://res.cloudinary.com/hxn9dbuhd/image/upload/v1774565149/wysiwyg/lw16lknptz7pwtra0dqt.jpg" style="width: 600px; display: block; vertical-align: top; margin: 5px auto; text-align: center; position: relative; max-width: 100%; cursor: pointer; padding: 0px 1px; user-select: none; box-sizing: inherit;" fr-original-style="width: 600px; display: block; vertical-align: top; margin: 5px auto; text-align: center;" fr-original-class="fr-draggable">hESC-derived human micro-beating-hearts uniformly positive to&nbsp;cardiomyocyte specific markers&nbsp;and spontaneously progress to beating&nbsp;with strong rhythmic impulses&nbsp;reminiscent of the p-QRS-T-complexes&nbsp;seen from body surface electrodes in clinical ECG. Due to lack of a scalable human neuron source, the need to restore vital tissue and function for a wide range of neurological diseases and injuries remains a daunting challenge to conventional drug development. SDRMI&rsquo;s innovative PluriXcel-SMI-Neuron Platform enables direct conversion of non-functional, clinical-grade hESCs at the pluripotent stage by small molecule induction uniformly into a large supply of human neuronal progenitor cells and functional neurons, providing the scalable manufacturing capability for large scale production of high quality, clinical-grade human neuronal cells adequate for neuron circuitry repair and nerve tissue bio-fabrication to fill the capability gap in nerve tissue and neurological/motor function restoration for a wide range of incurable or hitherto untreatable neurological diseases. SDRMI&rsquo;s hESC-based medical breakthrough innovation offers the only scalable source of human neurons adequate for nerve regeneration and neurological function restoration to treat serious, life threatening, progressive or fatal neurodegenerative diseases such as Parkinson&rsquo;s disease (PD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and injuries such as spinal cord injury (SCI), traumatic brain injury (TBI), and strokes. SDRMI has secured the patent [USPTO# 8,716,017] and exclusive rights for the development and commercialization of relevant hESC-based neuronal cell therapy products and tools.&nbsp; <img src="https://res.cloudinary.com/hxn9dbuhd/image/upload/v1774565278/wysiwyg/vwhexhoxgqf994rvwans.jpg" style="width: 600px; display: block; vertical-align: top; margin: 5px auto; text-align: center; position: relative; max-width: 100%; cursor: pointer; padding: 0px 1px; user-select: none; box-sizing: inherit;" fr-original-style="width: 600px; display: block; vertical-align: top; margin: 5px auto; text-align: center;" fr-original-class="fr-draggable">hESC-derived human micro-brains with extensive networks of neurite-bearing cells and pigmented cells (arrows), typical of those in the ventral mesencephalon. &nbsp; Chronic diseases are major causes of morbidity and mortality in the US and leading drivers of health care costs. Many chronic diseases are caused by damage or loss of tissue that leads to impairment or loss of function. The limit capacity of cardiomyocytes of the heart as well as neuron circuitries of the brain/spinal-cord for self-repair constitutes a significant challenge to traditional medicine for tissue and function restoration in seeking cures for those serious life-threatening diseases and injuries. To date, the need to restore vital tissue and function for a wide range of chronic diseases remains a daunting challenge to the conventional mode of drug development. In addition, there are acute shortages of donor organs in organ transplantation, such as heart transplantation, for many life-threatening diseases in order to save lives.&nbsp; Those devastating and life-threatening diseases are leading causes of death or permanent disability and major health problems that cost trillions in healthcare annually and affect millions of people in the US, but there is no effective treatment or drug that can restore the damaged or lost tissue and function. And many patients suffering from those life-threatening chronic diseases only have few years left to live and need urgent access to SDRMI&rsquo;s hESC-based cell therapy products that provide life-saving regenerative therapies. For example, ALS is a progressive, fatal neurodegenerative disease and most ALS patients die from respiratory failure, usually within 3 to 5 years from the onset of symptoms. Heart disease and stroke are the number one cause of death in the US. Around 6.7 million Americans survive heart failure but live with insufficient cardiac function, and the damage sustained by the heart may eventually develop into heart failure, with an estimated median survival of 1 to 2 years.&nbsp;&nbsp; SDRMI&rsquo;s Human Stem Cell Technology Platforms and Prototypes enable large-scale production of high quality, functional human neuron and heart-muscle cell/tissue/organ products to meet the demands of treatments or cures for a wide range of incurable or hitherto untreatable neurological and cardiovascular diseases. SDRMI&rsquo;s hESC-based game-changing technologies overcome the major bottlenecks in the regenerative medicine market and enables scalable nerve and heart tissue repair and bio-fabrication for many life-threatening and devastating diseases.&nbsp;&nbsp; Your contribution matters.&nbsp;&nbsp; Your donation accelerates patient access to urgently-needed, life-saving stem cell therapies.&nbsp; Give now and help save lives.

Hello <span contenteditable="false" data-custom-variable="{{firstname}}" fr-original-class="fr-deletable styled-tag-chip" fr-original-style="" style="background-color: rgb(248, 248, 255); border: 1px solid rgb(191, 191, 255); border-radius: 4px; color: rgb(42, 42, 196); padding: 1px 8px; font-size: 11px; display: inline-block; margin: 0px; overflow-wrap: anywhere; user-select: none; box-sizing: inherit;">First name, Thank you from the bottom of our hearts for supporting our cause. This donation greatly helps our mission. If you would like to contribute further to our cause, contact us to become a volunteer, or spread the word about our mission! Xuejun Parsonsparsons@sdrmi.org

🌟 Join us in Unleashing the Power of Life Sciences to Save Lives! 🌟 At San Diego Regenerative Medicine Institute (https://www.sdrmi.org), we develop scalable health solutions for life-threatening and devastating diseases, such as heart disease and failure, stroke, Parkinson’s disease (PD), Alzheimer disease (AD), spinal cord injury (SCI), traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), through most advanced, cutting-edge stem cell research. Every act of kindness, every dollar, and every moment of your time brings us closer to achieving our mission. Together, we can deliver urgently-needed, life-saving stem cell therapies to patients.  How you can help power our mission:<ol><li>Donate: Every dollar counts. Your contribution helps save lives. Give now to help us reach our goal.</li><li>Share: Share our campaign with your friends, family, and on social media. Your advocacy can amplify our impact.</li><li>Volunteer: Your time and skills can make an impact too.</li></ol>Thank you for supporting our mission, your support is invaluable. San Diego Regenerative Medicine Institute (SDRMI) was founded to leverage human embryonic stem cell (hESC)-based regenerative medicine development and manufacturing innovations to provide the next generation of cell-based therapeutic solutions for the unmet medical needs of many major health problems. SDRMI is a major innovator in the stem cell research and regenerative medicine market, and uniquely holds the key breakthrough technologies and exclusive rights for the major bottlenecks in the regenerative medicine market, including large-scale production of high quality, clinical-grade pluripotent hESC lines and their functional human heart and neuronal cell therapy products for commercial and therapeutic uses. SDRMI’s hESC-based PluriXcel technology platforms provide clinical-grade translating and scale-up manufacturing capabilities to address key challenges to traditional medicine and bio-fabrication. Medical innovations of PluriXcel Platforms provide scalable platforms to ensure a high degree of efficacy and safety of hESC-derived regenerative medicine advanced therapy (RMAT) products, thus robust clinical benefits leading to therapies. Manufacturing innovations of PluriXcel Platforms provide scalable cGMP manufacturing capability for production scale-up of large quantities of high quality, clinical-grade hESC-based cell therapy products to support clinical trials and tissue/organ bio-fabrication, improving the availability, reproducibility, accessibility, and standardization of manufacturing materials, technologies, and processes to create human replacement cells, tissues, and organs. SDRMI’s breakthrough hESC technology platforms not only constitute clinically representative progresses in both human cardiac and neuronal stem cell therapy products for treating a wide range of incurable or hitherto untreatable heart and neurological diseases and injuries, but also offers manufacturing innovation for production scale-up.   Lack of a scalable human cardiac stem cell source with adequate heart muscle regeneration potential remains a major setback for heart replacement, and fabricating a human heart is still beyond reach. SDRMI’s innovative PluriXcel-SMI-Heart Platform enables direct conversion of non-functional, clinical-grade hESCs at the pluripotent stage by small molecule induction uniformly into a large supply of human cardiac precursor cells and contractile cardiomyocytes (the mature contracting heart muscle cells), providing the scalable manufacturing capability for large-scale production of high-quality, clinical-grade human heart muscle cells adequate for heart muscle regeneration and bio-fabrication to fill the capability gap in myocardial tissue and contractile function restoration for heart disease and failure. SDRMI’s hESC-based medical breakthrough innovation offers the only scalable source of human cardiomyocytes adequate for heart muscle regeneration and contractile function restoration to treat heart disease and failure, and for heart bio-fabrication to meet the demand of replacement hearts in organ transplantation. SDRMI has secured the patent [USPTO# 9,428,731] and exclusive rights for the development and commercialization of relevant hESC-based heart cell therapy products and tools.  <img src="https://res.cloudinary.com/hxn9dbuhd/image/upload/v1774565149/wysiwyg/lw16lknptz7pwtra0dqt.jpg" style="width:600px;display:block;vertical-align:top;margin:5px auto;text-align:center;position:relative;cursor:pointer;padding:0px 1px;user-select:none;box-sizing:inherit;max-width:100%" />hESC-derived human micro-beating-hearts uniformly positive to cardiomyocyte specific markers and spontaneously progress to beating with strong rhythmic impulses reminiscent of the p-QRS-T-complexes seen from body surface electrodes in clinical ECG. Due to lack of a scalable human neuron source, the need to restore vital tissue and function for a wide range of neurological diseases and injuries remains a daunting challenge to conventional drug development. SDRMI’s innovative PluriXcel-SMI-Neuron Platform enables direct conversion of non-functional, clinical-grade hESCs at the pluripotent stage by small molecule induction uniformly into a large supply of human neuronal progenitor cells and functional neurons, providing the scalable manufacturing capability for large scale production of high quality, clinical-grade human neuronal cells adequate for neuron circuitry repair and nerve tissue bio-fabrication to fill the capability gap in nerve tissue and neurological/motor function restoration for a wide range of incurable or hitherto untreatable neurological diseases. SDRMI’s hESC-based medical breakthrough innovation offers the only scalable source of human neurons adequate for nerve regeneration and neurological function restoration to treat serious, life threatening, progressive or fatal neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and injuries such as spinal cord injury (SCI), traumatic brain injury (TBI), and strokes. SDRMI has secured the patent [USPTO# 8,716,017] and exclusive rights for the development and commercialization of relevant hESC-based neuronal cell therapy products and tools.  <img src="https://res.cloudinary.com/hxn9dbuhd/image/upload/v1774565278/wysiwyg/vwhexhoxgqf994rvwans.jpg" style="width:600px;display:block;vertical-align:top;margin:5px auto;text-align:center;position:relative;cursor:pointer;padding:0px 1px;user-select:none;box-sizing:inherit;max-width:100%" />hESC-derived human micro-brains with extensive networks of neurite-bearing cells and pigmented cells (arrows), typical of those in the ventral mesencephalon.   Chronic diseases are major causes of morbidity and mortality in the US and leading drivers of health care costs. Many chronic diseases are caused by damage or loss of tissue that leads to impairment or loss of function. The limit capacity of cardiomyocytes of the heart as well as neuron circuitries of the brain/spinal-cord for self-repair constitutes a significant challenge to traditional medicine for tissue and function restoration in seeking cures for those serious life-threatening diseases and injuries. To date, the need to restore vital tissue and function for a wide range of chronic diseases remains a daunting challenge to the conventional mode of drug development. In addition, there are acute shortages of donor organs in organ transplantation, such as heart transplantation, for many life-threatening diseases in order to save lives.  Those devastating and life-threatening diseases are leading causes of death or permanent disability and major health problems that cost trillions in healthcare annually and affect millions of people in the US, but there is no effective treatment or drug that can restore the damaged or lost tissue and function. And many patients suffering from those life-threatening chronic diseases only have few years left to live and need urgent access to SDRMI’s hESC-based cell therapy products that provide life-saving regenerative therapies. For example, ALS is a progressive, fatal neurodegenerative disease and most ALS patients die from respiratory failure, usually within 3 to 5 years from the onset of symptoms. Heart disease and stroke are the number one cause of death in the US. Around 6.7 million Americans survive heart failure but live with insufficient cardiac function, and the damage sustained by the heart may eventually develop into heart failure, with an estimated median survival of 1 to 2 years.   SDRMI’s Human Stem Cell Technology Platforms and Prototypes enable large-scale production of high quality, functional human neuron and heart-muscle cell/tissue/organ products to meet the demands of treatments or cures for a wide range of incurable or hitherto untreatable neurological and cardiovascular diseases. SDRMI’s hESC-based game-changing technologies overcome the major bottlenecks in the regenerative medicine market and enables scalable nerve and heart tissue repair and bio-fabrication for many life-threatening and devastating diseases.   Your contribution matters.   Your donation accelerates patient access to urgently-needed, life-saving stem cell therapies.  Give now and help save lives.

Donate to Speed Stem Cell Medical Breakthrough Innovations to Patients to Save Lives

IsFundraiserFormEditDisabled

IsPaymentByPadAllowed

San Diego Regenerative Medicine Institute

**San Diego Regenerative Medicine Institute Context Profile**

1. **Organization Mission & Cause:**
   - The San Diego Regenerative Medicine Institute (SDRMI) is dedicated to advancing the field of regenerative medicine through research, education, and collaboration. Their mission is to harness the power of regenerative technologies to improve health outcomes and enhance the quality of life for individuals. They focus on developing innovative treatments and therapies that leverage the body's natural healing processes.

2. **Type of Activities:**
   - **Research Initiatives:** SDRMI is heavily involved in conducting cutting-edge research in regenerative medicine, aiming to discover new therapies and improve existing ones.
   - **Educational Programs:** The institute offers educational resources and programs to inform both the scientific community and the public about the latest advancements in regenerative medicine.
   - **Collaborative Projects:** They engage in partnerships with other research institutions, healthcare providers, and industry leaders to foster innovation and accelerate the development of regenerative treatments.

3. **Tone of Voice:**
   - The tone of SDRMI's communications is professional and informative, reflecting their scientific focus and commitment to advancing medical knowledge. The language is precise and aimed at both an educated audience and the general public interested in medical advancements.

4. **Emoji Usage:**
   - There is no evidence of emoji usage in SDRMI's communications on their website. Their content maintains a formal and professional tone, which is typical for scientific and research-focused organizations.

5. **Key Facts:**
   - **Founding Info:** SDRMI is a newly established organization, indicating a fresh and innovative approach to regenerative medicine.
   - **Impact Metrics:** While specific impact metrics are not detailed, the institute emphasizes its commitment to pioneering research and educational outreach.
   - **Volunteer Info:** There is no specific information on volunteer opportunities, suggesting a primary focus on professional research and collaboration.

6. **Writing Guidelines:**
   - **Style:** Use clear, concise, and professional language that communicates complex scientific concepts in an accessible manner.
   - **Content Focus:** Emphasize the innovative and collaborative nature of their work, highlighting breakthroughs and partnerships.
   - **Audience Engagement:** While maintaining professionalism, aim to inspire interest and curiosity in regenerative medicine advancements.
   - **Avoid Informality:** Given the lack of emoji usage and the formal tone, avoid informal language or casual expressions.

This context profile provides a comprehensive understanding of the San Diego Regenerative Medicine Institute, allowing AI assistants to generate content that aligns with their mission and communication style.

San Diego Regenerative Medicine Institute

Donate to Speed Stem Cell Medical Breakthrough Innovations to Patients to Save Lives

Choose an amount:

$